5th Congress of the Mediterranean Multidisciplinary Oncology Forum

23-25 November 2017 | Hilton Athens | Greece

Accreditation: 12 CME - CPD points - Panhellenic Medical Association

Under the auspices of:

- Hellenic Society of Medical Oncology
- National Cancer Institute of Egypt
- Turkish Society of Medical Oncology

www.medmof2017.com

Scientific Program

In collaboration with:
Dear Colleagues,

It is a great pleasure and honor for me to announce the organization of the 5th Mediterranean Multidisciplinary Oncology Forum (MMOF) Congress, which will be held in Athens, in November 23-25, 2017.

The 5th MMOF Congress is expected to be a lively International Forum for oncology professionals across the Mediterranean, to meet, integrate, discuss and share ideas and communicate new developments in Oncology for the advancement of cancer care across the Mediterranean Sea.

An innovative Scientific Program has been designed to cover a wide range of topics, with a prestigious faculty of Oncology experts, representing various disciplines to share new practices in the field of Oncology.

The Congress will feature round tables, panel discussions of challenging cases, oral presentations, posters and special workshops for young oncologists. The program will also encompass a special scientific event, “The Immuno-Oncology Day”, where the revolution of Immunotherapy will be illustrated by world opinion leaders in the field.

We are looking forward to welcoming you in Athens, to experience a unique scientific event and to rejoice in the greatness of Greek culture and civilization in the historical city of Athens.

Dimitrios I. Bafaloukos, MD, PhD
President of the 5th MMOF Congress
ORGANIZING COMMITTEE
(BOARD OF DIRECTORS OF MMOF)

Honorary Presidents
P. Kosmidis, Greece
H. Onat, Turkey

President
D. Bafaloukos, Greece

Vice Presidents
G. Asimakopoulos+, Greece
G. Demir, Turkey

Gen. Secretaries
O. Khorshid, Egypt
H. Linardou, Greece
B. Oyan Uluc, Turkey

Gen. Educ. Secretary
A. Christopoulou, Greece
P. Saip, Turkey

Treasurer
O. Nicolatou-Galitis, Greece

Members
I. Yucel, Turkey
M. Garassino, Italy
Local Organizing Committee

Chairman:
D. Bafaloukos

Members:
Ch. Andreadis
I. Boukovinas
A. Dimopoulos
G. Koumakis
A. Laskarakis
M. Nikolaou
F. Poulakaki
E. Samantas
A. Tarampikou
K. Tsigaridas

Scientific Committee

Chairpersons:
I. Athanasiadis, Greece
H. Linardou, Greece
M. Gümüş, Turkey
R. Gaafar, Egypt

Members:
S. Agelaki, Greece
G. Aravantinos, Greece
A. Ardavanis, Greece
V. Barbounis, Greece
S. Bavbek, Turkey
R. Berardi, Italy
N. Bese, Turkey
A. Boleti, UK
P. Dimovelis, Greece
K. Frangia, Greece
S. Kakolyris, Greece
H. Khaled, Egypt
D. Mavroudis, Greece
I. Mountzios, Greece
M. Mokhtar, Egypt
S. Murray, UK
G. Pentheroudakis, Greece
A. Stratigos, Greece
I. Varthalitis, Greece
O. Zoras, Greece
International Advisory Committee

Members:
A. Bouncedjar, Algeria
Th. Economopoulos, Greece
Z. Fahed, Syrian Arab Republic
G. Fountzilas, Greece
F. Geara, Lebanon
V. Georgoulis, Greece
H. Gogas, Greece
M. Gottfried, Israel
G. Leone, Italy
H. Nina, Albania
N. Normanno, Italy
B. Oyan Uluc, Turkey
E. Ozyar, Turkey
D. Pectasides, Greece
A. Psyrri, Greece
E. Razis, Greece
K. Syrigos, Greece

Abstract Review Committee

O. Er, Turkey
M. Garassino, Italy
Th. Makatsoris, Greece
S. Murray, UK
S. Naguib, Egypt
Z. Saridaki, Greece

Award Committee

Ch. Bakoyiannis, Greece
Ch. Christodoulou, Greece
N. Kentepozidis, Greece
O. Khorshid, Egypt
H. Linardou, Greece
P. Saip, Turkey
P. Veronesi, Italy
16:00-17:00  **Young MMOF – Mentorship session**  
Bridging approaches in the Mediterranean: Brainstorming on interesting cases  
Chairs: *N. Al Lahloubi (EG), M. Nikolaou (GR), K. Tsigaridas (GR)*  

- **Neuroendocrine cancer**  
  - case presentation (junior oncologist): S. Ziampiri (IT)  
  - mentor’s opinion: A. Strimpakos (GR)  

- **Mesothelioma**  
  - case presentation (junior oncologist): O. Tsavaris (GR)  
  - mentor’s opinion: N. Al Lahloubi (EG)  

- **Gynaecological cancer**  
  - case presentation (junior oncologist): T. Kyriazoglou (GR)  
  - mentor’s opinion: K. Sakellariou (GR)  

17:00-18:00  **Advances in GU cancers**  
Chairs: *S. Bavbek (TR), A. Christopoulou (GR), N. Kentepozidis (GR)*  

- The robotic era in renal and prostate surgical oncology.  
  - Renal cancer: treatment choices and changes in algorithms.  
  - Castration-resistant prostate cancer: what is new?  
  - V. Poulakis (GR)  
  - E. Boleti (UK)  
  - C. Panopoulos (GR)  

18:00-19:00  **GI cancer, non-colorectal**  
Chairs: *G. Demir (TR), C. Dervenis (GR), P. Papakostas (GR)*  

- Gastric cancer in the Mediterranean basin.  
  - Epidemiological data and clinical challenges.  
  - Neoadjuvant therapy in gastric cancer.  
  - Redux with FLOT.  
  - S. Yalcin (TR)  
  - A. Strimpakos (GR)  

- Opportunities in locally advanced pancreatic cancer.  
  - Surgical perspective: G. Tsitotos (GR)  
  - Medical perspective: M. El-Serafi (EG)  

19:00-19:30  **Coffee Break**  

19:30-20:00  **Lecture**  
Chairs: *H. Khaled (EG), P. Kosmidis (GR), H. Onat (TR)*  

- The European Society of Medical Oncology  
  - Magnitude of clinical benefit scale.  
  - G. Pentheroudakis (GR)
In Memoriam George Asimakopoulos

Defaults are shifting: As the biology of breast cancer is more disclosed, lesser the loco-regional treatment it requires.

B. Gulluoglu (TR)

Oral presentations session 1

O1: 15-YEAR EXPERIENCE WITH MINOR SALIVARY GLAND CANCER AT SINGLE INSTITUTION: A CLINICAL-PATHOLOGICAL STUDY.
I. Kalaitsidou, K. Vahtsevanos, I. Tilaveridis, K. Paraskevopoulos, N. Pastelli, I. Dimitriadis, K. Antoniades

O2: METASTATIC TUMORS TO THE ORAL CAVITY
I. Kalaitsidou, K. Paraskevopoulos, K. Vahtsevanos, I.S. Astreidis, V. A. Alexoudi, K. Antoniades

O3: EXPLORING CANCER PREDISPOSITION: PERFORMANCE OF A 94-GENE PANEL ON GREEK BREAST AND OVARIAN CANCER PATIENTS FULFILLING THE NCCN CRITERIA FOR GENETIC TESTING.
F. Fostira, I. Konstantopoulo, M.S. Pamantzelopoulo, D. Kalfakakou, A. Vagena, P. Apostolou, I. Konstanta, A. Delimitsou, I.S. Vlachos, D. Yannoukakos

O4: NGS ANALYSIS OF HEREDITARY CANCER SYNDROMES: MORE ANSWERS THAN QUESTIONS.

O5: APPLICATION OF NEXT GENERATION SEQUENCING IN LIQUID BIOPSY ANALYSIS.

O6: MRI DWIBS IN ASSESSMENT OF CANCER PATIENTS; COULD BE HELPFUL?
M. Rezk

O7: THE ROLE OF INTRA OPERATIVE MOBILE GAMMA CAMERA AND GAMMA PROBE IN DETECTION OF SENTINEL LYMPH NODE IN EARLY STAGE BREAST CANCER (THE EGYPTIAN EXPERIENCE).
M. Gamil, M. Hassan, M. Salama, O. Talaat, K. Khalifa Alla, S. Abd AlGaid, A. Mohamed

O8: THE AVOIDANCE OF THE LIP CONTRACTION AFTER THE CUNEIFORM NEOPLASIA EXCISION, USING THE VERMILION FLAP.
D. G. Xhepa, H. Nina, A. Hafizi

O9: NIVOLUMAB PLUS IPILIMUMAB IN METASTATIC MELANOMA: SINGLE CENTRE EXPERIENCE.
D. Bafaloukos, A. Laskarakis, A. Tarampikou, K. Gkiati, A. Molfeta, K. Tsigaridas, A. Bousboukea, H. Linardou
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-14:00</td>
<td><strong>Immuno-Oncology: A new era in cancer</strong></td>
<td>I. Athanasiadis (GR), M. Gumus (TR), O. Khorshid (EG)</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Fundamental concepts on I-O.</td>
<td>M. Lotem (IL)</td>
<td></td>
</tr>
<tr>
<td>09:30-11:30</td>
<td>Clinical aspects on I-O.</td>
<td>T. Kubiatowski (PL)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Melanoma: the basis of a new era of success</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Progress in Immuno-Oncology Research for</td>
<td>R. Leibowitz (IL)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal and Bladder Cancers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• SCCHN: Does immunotherapy change the</td>
<td>A. Psyrri (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>treatment landscape?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• NSCLC: The perspective of Immunotherapy-</td>
<td>J. Bar (IL)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Current challenges</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td><strong>Coffee Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00-14:00</td>
<td><strong>Practical considerations in Immuno-Oncology</strong></td>
<td>D. Bafaloukos (GR), A. Stratigos (GR)</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Immunotherapy in the adjuvant setting-new</td>
<td>H. Gogas (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>options and perspectives.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Toxicity and supportive care of the patient</td>
<td>V. Nikolaou (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>on I-O</td>
<td>E. Kassi (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The perspective of:</td>
<td>A. Charpidou (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dermatologist:</td>
<td>G. Bamias (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Endocrinologist:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Pneumonologist:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Gastrenterologist:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-14:00</td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00-14:45</td>
<td><strong>Parallel satellite lecture</strong></td>
<td>Th. Economopoulos (GR), P. Pantelakos (GR)</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>Chairs:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Advances in NSCLC: The unmet need in</td>
<td>H. Linardou (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>early stage III.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Esperides Hall

**15:30-19:00** Evolution in lung cancer care in the era of CIT.  
**Chairs:** G. Demir (TR), R. Gaafar (EG), H. Linardou (GR)  
**15:30-16:00** Identifying the right patient for the right treatment.  
**N. Peled (IL)**  
**16:00-16:30** The emerging role of cancer immunotherapy in NSCLC.  
**M. Gottfried (IL)**  
**16:30-17:00** A series of success stories in the personalized approaches for lung cancer: the example of ALK+ NSCLC.  
**E. Felip (SP)**  
**17:00-17:30** Coffee Break

### Esperides Hall

**17:00-17:30** Coffee Break

**17:30-18:30** Building the treatment algorithm in the era of cancer immunotherapy.  
- EGFR mutant disease: R. Gaafar (EG)  
- ALK and other biomarker - positive disease: A. Laskarakis (GR)  
- CIT: G. Mountzios (GR)  
- Antiangiogenesis: G. Oikonomopoulos (GR)

**18:30-19:00** Closing-Overview to current NSCLC treatment guidelines.  
**E. Felip (SP)**

### Esperides Hall

**19:00-20:30** Opening Ceremony  
**Chairs:** D. Bafaloukos (GR), H. Onat (TR), O. Zoras (GR)  
**Paris Kosmidis Award**  
**Keynote Lecture on Lung cancer** J.-Y. Douillard (FR)  
**Welcome addresses**

**Opening Lecture**  
Literary and artistic representations of women’s cancer  
**V. Rapti (US)**

### Santorini Hall

**11:30-12:30** Breast Surgeon’s Working Group of MMOF
09:00-10:30  Colorectal cancer
Chairs: G. Demir (TR), N. Mokhtar (EG), Z. Saridaki (GR)

Adjuvant therapy of colon cancer. Molecular classification and good IDEAs. G. Demir (TR)

Integration of systemic therapies with local therapies in unresectable hepatic metastases. G. Tzimas (GR)

Chemotherapy and targeted agents in 1st line. E. Martinelli (IT)

Sequencing of systemic therapies in metastatic disease beyond 1st line. O. Er (TR)

10:30-12:00  Medical oncology in the Mediterranean
Chairs: I. Boukovinas (GR), S. Murray (UK)

Multidisciplinarity - a dream or everyday reality? I. Boukovinas (GR)

Prevention/early diagnosis - molecular diagnostic tests for all? the scientist’s view. G. Sozzi (IT)

Access to cancer therapies - inequalities and challenges. K. Athanasakis (GR)

Access to cancer therapies: examples from eastern Mediterranean countries. Z. Fahed (SY)

The patients’ perspective K. Apostolidis (GR)

Commentators: I. Yucel (TR), G. Samonis (GR), M. Garassino (IT), S. Neta (GR)

12:00-12:30  Coffee Break

12:30-14:00  Breast cancer
Chairs: H. Khaled (EG), G. Koumakis (GR), H. Nina (AL)

Surgical approach after neoadjuvant chemotherapy for breast cancer. F. Poulakaki (GR)

PARP inhibitors in breast cancer. Clinical data and emerging opportunities. E. Galani (GR)

Her2 targeting in the neoadjuvant and adjuvant setting. Critical analysis of the data. Ch. Christodoulou (GR)

Luminal breast cancers. Appropriate treatment sequencing and individualized decisions. O. Khorshid (EG)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairs</th>
<th>Sponsored by</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:00</td>
<td>Lunch Break and Parallel satellite lectures</td>
<td><em>P. Kosmidis (GR), H. Linardou (GR)</em></td>
<td><em>M. Garassino (IT)</em></td>
</tr>
<tr>
<td></td>
<td>Immunotherapy in lung cancer: a choice for everyone?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td><strong>Chairs:</strong> P. Kosmidis (GR), H. Linardou (GR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>Chairs:</strong> V. Georgoulas (GR), P. Dimovelis (GR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Agreements and disagreements in targeted melanoma therapies.</td>
<td></td>
<td><em>Roche</em></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>Chairs:</strong> V. Georgoulas (GR), P. Dimovelis (GR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sponsored by:</strong> M. Garassino (IT)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-16:00</td>
<td><strong>Supportive care and toxicity management</strong></td>
<td><em>M. Gumus (TR), S. Kaltzas (GR), E. Patiraki (GR)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> M. Gumus (TR), S. Kaltzas (GR), E. Patiraki (GR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Advances in pain management.</td>
<td>Z. Kontouli (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>New drugs, new toxicities- basic management steps.</td>
<td>I. Athanasiadis (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiotoxicity in oncology- new ways to approach it.</td>
<td>M. Mahmoudi (UK)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The role of specialised oncology nurses.</td>
<td>A. Tarampikou (GR)</td>
<td></td>
</tr>
<tr>
<td>16:00-17:00</td>
<td><strong>Head and neck cancer</strong></td>
<td><em>M. El Serafi (EG), I. Giotakis (GR), O. Nicolatou-Galitis (GR)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> M. El Serafi (EG), I. Giotakis (GR), O. Nicolatou-Galitis (GR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>State of the art radiation therapy for head and neck cancer.</td>
<td>A. Dimopoulos (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HPV infection and classification schemas for oropharyngeal cancer.</td>
<td>K. Tsigaridas (GR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sequencing of therapies and therapeutic algorithm in squamous cell head and neck cancer.</td>
<td>A. Psyrri (GR)</td>
<td></td>
</tr>
<tr>
<td>17:00-17:30</td>
<td><strong>Closing and Awards (best abstract)</strong></td>
<td><em>I. Athanasiadis (GR), R. Gaafar (EG), M. Gumus (TR), H. Linardou (GR)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> I. Athanasiadis (GR), R. Gaafar (EG), M. Gumus (TR), H. Linardou (GR)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
09:00-10:00 Oral presentations session 2
Chairs: S. Kosmidis (GR), C. Panopoulos (GR)

O10: MUCH MORE THAN WE DO BELIEVE, HORMONE CONTRACEPTION IS A MAJOR RISK FACTOR FOR BREAST CANCER. UPPER EGYPT POPULATION STUDY.
I. Malash, E. Desouky

O11: B.C.S. & ONCOPLASTIC RECONSTRUCTION IN BREAST CANCER PATIENTS N.C.I. EXPERIENCE.
M.M. Safa, W. Yousry, O. Zakaria, A. Farahat

O12: SURGERY IN BREAST AFTER NEOADJUVANT THERAPY.

O13: GRANULOSA CELL TUMORS OF THE OVARY; RETROSPECTIVE ANALYSIS OF 17 CASES.
H. Aziz, A. Fathalla

O14: PRIMARY OVARIAN NON-HODGKIN’S LYMPHOMA: A CLINICO-PATHOLOGIC STUDY OF 16 CASES.
H. Aziz, A. Fathalla

O15: SEXUALITY IN PATIENTS TREATED FOR COLORECTAL CANCER.
G. Tassopoulos, A. Stefanopoulos, M. Hera, A. Hatzopoulos, P. Heras

O16: D2 GASTRECTOMY: LONG TERM RESULTS.
A. Touny

O17: MALIGNANT PLEURAL MESOTHELIOMA (MPM) AMONG DECADES.
R. M. Gaafar, F.M.A. Abou El-kasem, M. Abdel-Rahman, M. Rahoma, I. Ioai AbouEl-khir

O18: ONCOGENIC MECHANISMS IN MALIGNANT PLEURAL EFFUSION DUE TO PRIMARY LUNG ADENOCARCINOMA.
General Informations

Organized by the
Mediterranean Multidisciplinary Oncology Forum (M.M.O.F.)

Congress website
www.medmof2017.com

Congress Dates
23-25 November 2017

Congress Venue
Hotel Hilton Athens
46, Vassilisis Sofias Avenue,
115 28 Athens
Tel +30 210 7281000

Language
The official language of the Congress is English.

Audiovisual - Technical Support
All meeting rooms will be equipped with data video projectors, laser pointers etc, for power point presentations. Technical Support Center will be available outside the meeting rooms. Technical staff will assist with the presentations. All speakers are kindly requested to submit their presentation at least 1 hour prior to their scheduled presentation.

Accreditation
The 5th Congress of the Mediterranean Multidisciplinary Oncology Forum will receive accreditation from the Panhellenic Medical Society.

Name badges
All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance.

Congress Secretariat

E.T.S. Events & Travel Solutions S.A.
154 El. Venizelou Str.
171 22 Athens, Greece,
Tel.: +30 210 98 80 032
Fax.: +30 210 98 81 303
E-mail: ets@events.gr, ets@otenet.gr,
Website: www.events.gr
Certificate of Attendance
All registered participants who have attended at least 60% of the total program hours will receive a certificate of attendance from the Secretariat Desk after the closing ceremony.

Registration Cost (VAT included)

<table>
<thead>
<tr>
<th>Type of Registration</th>
<th>Up to September 01st 2017</th>
<th>After September 02nd 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMOF Members</td>
<td>130€</td>
<td>200€</td>
</tr>
<tr>
<td>Non-MMOF Members</td>
<td>170€</td>
<td>240€</td>
</tr>
<tr>
<td>Oral Oncologists &amp; Junior Oncologists, Nurses</td>
<td>70€</td>
<td>130€</td>
</tr>
<tr>
<td>Daily registration ticket</td>
<td>50€</td>
<td></td>
</tr>
<tr>
<td>Medical Students</td>
<td>Free</td>
<td>Free</td>
</tr>
</tbody>
</table>

Registration cost includes:
- Admission to all conference sessions & exhibition area
- Congress proceedings – material, certificate of attendance
  - Full payment is required for all registrations.

Registration for medical students includes:
- Admission to all conference sessions & exhibition area
- Certificate of attendance

Accommodation Cost
Limited number of rooms has been pre-booked at the Hilton Athens Hotel with special conditions for the Congress’ participants.

Please visit the site www.medmof2017.com to download the booking form in order to guarantee and confirm your registration.